Independent publication supports the profile of CeNeS phase II compound, CNS 5161
CAMBRIDGE, England, 4th May 2007 - CeNeS Pharmaceuticals plc (LSE: CEN), the Cambridge based biopharmaceutical company, notes the publication of an independent study in the respected scientific journal 'Synapse'* on its Phase II NMDA antagonist, CNS 5161. CeNeS is developing CNS 5161 as a potentia...Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
CAMBRIDGE, U.K. 2nd July 2007 - CeNeS Pharmaceuticals (AIM:CEN) ("CeNeS" or "the Company") the Cambridge-based biopharmaceutical company today announced that a paper published this week in CNS Drugs(1) further supports the hypothesis that a catechol-O-methyltransferase (COMT) inhibitor that acts i...CeNeS Pharmaceuticals plc: Update on Successful Phase III results announced on Lead Product M6G
...rative pain CAMBRIDGE, England, 7th March 2007 - cenes Pharmaceuticals plc (AIM: CEN), the Cambridge base...ts The additional secondary data now received by cenes shows that: * less anti-emetic drugs (drugs used...mproved patient comfort due to lower PONV supports cenes justification of a substantial price premium for M...CeNeS Pharmaceuticals Plc Announces Preliminary Results for The Year Ending 31 December 2006
...6G underway CAMBRIDGE, England, March 28, 2007 - cenes Pharmaceuticals plc ("CeNeS" or "the Company"), th...near-term." For more information please contact: cenes Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)12...n/Emma Thompson Tel: + 44 (0) 207 831 3113 About cenes Pharmaceuticals...FDA approves IND on Lead Product M6G
... CAMBRIDGE, England, 26th April 2007 - cenes Pharmaceuticals plc (LSE: CEN), the Cambridge base...y analysis before progressing to Phase III trials. cenes is currently completing the protocol design of the...e therapy." For more information please contact: cenes Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)12...